Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of chinese patients

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Huang, Ying ^a   Ye, Sheng ^b   Cao, Yabing ^a,c   Li, Zhiming ^a   Huang, Jiajia ^a   Huang, He ^a   Cai, Muyan ^a   Luo, Rongzhen ^a   Lin, Tongyu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Macao Special Administrative Region of the People's Republic of China   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R CHOP PROTOCOL; R-CHOP PROTOCOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHINESE; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; CHINA; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GERMINAL CENTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84870222639     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/897178     Document Type: Article

References (20)

1. Armitage J. O., A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997 89 11 3909 3918 2-s2.0-1842413105 (Pubitemid 27220933)
2. Alizadeh A. A., Elsen M. B., Davis R. E., Ma C. L., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marü G. E., Moore T., Hudson J., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 6769 503 511 2-s2.0-0034598746 10.1038/35000501 (Pubitemid 30082188)
3. Hans C. P., Weisenburger D. D., Greiner T. C., Gascoyne R. D., Delabie J., Ott G., Müller H. K., Campo E., Braziel R. M., Jaffe E. S., Pan Z., Farinha P., Smith L. M., Falini B., Banham A. H., Rosenwald A., Staudt L. M., Connors J. M., Armitage J. O., Chan W. C., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 1 275 282 2-s2.0-9144237554 10.1182/blood-2003-05-1545 (Pubitemid 38029949)
4. Rosenwald A., Wright G., Chan W. C., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine 2002 346 25 1937 1947 10.1056/NEJMoa012914 (Pubitemid 34651353)
5. Wilson W. H., Jung S.-H., Porcu P., Hurd D., Johnson J., Eric Martin S., Czuczman M., Lai R., Said J., Chadburn A., Jones D., Dunleavy K., Canellos G., Zelenetz A. D., Cheson B. D., Hsi E. D., A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012 97 5 758 765 10.3324/haematol.2011.056531
6. Gu K., Weisenburger D. D., Fu K., Chan W. C., Greiner T. C., Aoun P., Smith L. M., Bast M., Liu Z., Bociek R. G., Bierman P. J., Armitage J. O., Vose J. M., Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematological Oncology 2012 30 3 143 149 10.1002/hon.1017
7. Zinzani P. L., Broccoli A., Stefoni V., Musuraca G., Abruzzese E., De Renzo A., Cantonetti M., Bacci F., Baccarani M., Pileri S. A., Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010 116 24 5667 5675 2-s2.0-78650158119 10.1002/cncr.25307
8. Ninan M. J., Wadhwa P. D., Gupta P., Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leukemia and Lymphoma 2011 52 3 360 373 2-s2.0-79951700897 10.3109/10428194.2010.543716
9. Sehn L. H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K. J., Shenkier T., Sutherland J., Gascoyne R. D., Connors J. M., The revised international prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007 109 5 1857 1861 2-s2.0-33847361987 10.1182/blood-2006-08-038257 (Pubitemid 46348180)
10. Lenz G., Wright G., Dave S. S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., Vose J., Bast M., Fu K., Weisenburger D.D., Greiner T.C., Armitage J.O., Kyle A., May L., Gascoyne R.D., Connors J.M., Troen G., Holte H., Kvaloy S., Dierickx D., Verhoef G., Delabie J., Smeland E.B., Jares P., Martinez A., Lopez-Guillermo A., Montserrat E., Campo E., Braziel R.M., Miller T.P., Rimsza L.M., Cook J.R., Pohlman B., Sweetenham J., Tubbs R.R., Fisher R.I., Hartmann E., Rosenwald A., Ott G., Muller-Hermelink H.-K., Wrench D., Lister T.A., Jaffe E.S., Wilson W.H., Chan W. C., Staudt L. M., Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine 2008 359 22 2313 2323 10.1056/NEJMoa0802885
11. Choi W. W. L., Weisenburger D. D., Greiner T. C., Piris M. A., Banham A. H., Delabie J., Braziel R. M., Geng H., Iqbal J., Lenz G., Vose J. M., Hans C. P., Fu K., Smith L. M., Li M., Liu Z., Gascoyne R. D., Rosenwald A., Ott G., Rimsza L. M., Campo E., Jaffe E. S., Jaye D. L., Staudt L. M., Chan W. C., A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research 2009 15 17 5494 5502 2-s2.0-68549124173 10.1158/1078-0432.CCR-09-0113
12. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte. Journal of Clinical Oncology 2005 23 18 4117 4126 2-s2.0-23044503407 10.1200/JCO.2005.09.131 (Pubitemid 46211317)
13. Wilson W. H., Dunleavy K., Pittaluga S., Hegde U., Grant N., Steinberg S. M., Raffeld M., Gutierrez M., Chabner B. A., Staudt L., Jaffe E. S., Janik J. E., Phase II study of dose-Adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology 2008 26 16 2717 2724 2-s2.0-45749152667 10.1200/JCO.2007.13.1391
14. Nyman H., Adde M., Karjalainen-Lindsberg M. L., Taskinen M., Berglund M., Amini R. M., Blomqvist C., Enblad G., Leppä S., Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007 109 11 4930 4935 2-s2.0-34249673388 10.1182/blood-2006-09-047068 (Pubitemid 46827791)
15. Seki R., Ohshima K., Fujisaki T., Uike N., Kawano F., Gondo H., Makino S., Eto T., Moriuchi Y., Taguchi F., Kamimura T., Tsuda H., Ogawa R., Shimoda K., Yamashita K., Suzuki K., Suzushima H., Tsukazaki K., Higuchi M., Utsunomiya A., Iwahashi M., Imamura Y., Tamura K., Suzumiya J., Yoshida M., Abe Y., Matsumoto T., Okamura T., Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Science 2009 100 10 1842 1847 2-s2.0-70349603639 10.1111/j.1349-7006.2009.01268.x
16. Czuczman M. S., Grillo-López A. J., Alkuzweny B., Weaver R., Larocca A., Mclaughlin P., Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leukemia and Lymphoma 2006 47 9 1830 1840 2-s2.0-33750481565 10.1080/10428190600709523 (Pubitemid 44649768)
17. Koivula S., Valo E., Raunio A., Hautaniemi S., Leppä S., Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. Oncology Reports 2011 25 4 1183 1190 2-s2.0-79952232721 10.3892/or.2011.1179
18. Davis R. E., Brown K. D., Siebenlist U., Staudt L. M., Constitutive nuclear factor κ B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 2001 194 12 1861 1874 2-s2.0-0035905313 10.1084/jem.194.12.1861 (Pubitemid 34028664)
19. Lam L. T., Davis R. E., Ngo V. N., Lenz G., Wright G., Xu W., Zhao H., Yu X., Dang L., Staudt L. M., Compensatory IKK α activation of classical NF- κ B signaling during IKK β inhibition identified by an RNA interference sensitization screen. Proceedings of the National Academy of Sciences of the United States of America 2008 105 52 20798 20803 2-s2.0-58549104540 10.1073/pnas.0806491106
20. Yeung K., Janosch P., McFerran B., Rose D. W., Mischak H., Sedivy J. M., Kolch W., Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Molecular and Cellular Biology 2000 20 9 3079 3085 2-s2.0-0034003003 10.1128/MCB.20.9.3079-3085.2000 (Pubitemid 30215020)